Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: j_fir2 who wrote (3301)	6/16/1999 4:33:00 PM
From: Neuroguy	Respond to of 10280

(OT) epilepsy Well, there has been a huge amount of work on various models of epilepsy, and what I can say is that epilepsy is a family of diseases with overlapping symptomology (seizures). So there is no single underlying mechanism. We know a lot about how epilepsies could develop, but are not yet certain how they do develop in all cases. But with further developments in non-invasive brain imaging and molecular biological approaches, the answers to many epilepsies could firm up fairly soon. This lack of knowledge has led to the development of a slew of drugs which, while effective in certain patient populations, have largely unknown mechanisms of action. Most of them are just non-specific neural depressants. The UCB compound looks very promising though, since it lacks these non-specific effects, yet potently suppresses seizures. End of lesson! Grinding my teeth today because my favorite biotech, CLPA, had a huge news release and conference call, and the MMs and momentum traders knocked the price to bits. Grrr..... Reminds me of the brief CNBC-inspired spike to 140 of SEPR. NeuroDude